OR WAIT null SECS
Bridge Laboratories (Gaithersburg, MD), a preclinical contract research organization, will build its second preclinical facility in China.
Bridge Laboratories (Gaithersburg, MD), a preclinical contract research organization, will build its second preclinical facility in China. This 150,000-square foot facility will be adjacent to Bridge’s existing laboratory in the Zhongguancun Life Sciences Park located in Beijing, China and will quadruple Bridge’s available laboratory space in Beijing.
Construction of the new laboratory will begin in the fourth quarter of 2008 and is expected to be completed in late fourth quarter of 2009. The state-of-the-art facility, being designed to meet US Food and Drug Administration and worldwide regulatory standards, will provide GLP toxicology, immunology, vaccine, and bioanalytical services.
Bridge Laboratories provides US-level regulatory compliant drug development services globally. Bridge’s existing facility in Beijing was designed to be both Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) multi-species accredited and US-level good laboratory practices (GLP) compliant.
Bridge Laboratories release